PD-Rx Pharmaceuticals, Inc. (PDRX)
OTCMKTS
· Delayed Price · Currency is USD
2.760
+0.010 (0.36%)
At close: Apr 16, 2025
PD-Rx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
Cash & Equivalents | 5.4 | 6.83 | 5.47 | 2.9 | 3.46 | Upgrade
|
Cash & Short-Term Investments | 5.4 | 6.83 | 5.47 | 2.9 | 3.46 | Upgrade
|
Cash Growth | -20.93% | 24.87% | 88.38% | -15.96% | 9.41% | Upgrade
|
Receivables | 3.18 | 2.38 | 4.46 | 3.89 | 2.3 | Upgrade
|
Inventory | 2.23 | 1.64 | 1.84 | 2.65 | 1.85 | Upgrade
|
Other Current Assets | 0.53 | 0.54 | 0.22 | 0.55 | 0.28 | Upgrade
|
Total Current Assets | 11.35 | 11.39 | 11.98 | 10 | 7.88 | Upgrade
|
Property, Plant & Equipment | 1.44 | 1.52 | 1.24 | 0.83 | 0.85 | Upgrade
|
Long-Term Deferred Tax Assets | - | 0.03 | - | 0.07 | 0.07 | Upgrade
|
Total Assets | 12.78 | 12.95 | 13.22 | 10.9 | 8.79 | Upgrade
|
Accounts Payable | 1.52 | 0.99 | 1.16 | 1.65 | 0.58 | Upgrade
|
Accrued Expenses | 0.76 | 0.7 | 0.7 | 0.77 | 0.65 | Upgrade
|
Total Current Liabilities | 2.28 | 1.7 | 1.86 | 2.42 | 1.23 | Upgrade
|
Long-Term Debt | - | - | - | - | 0.93 | Upgrade
|
Long-Term Deferred Tax Liabilities | 0 | - | 0.01 | - | - | Upgrade
|
Total Liabilities | 2.29 | 1.7 | 1.87 | 2.42 | 2.16 | Upgrade
|
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | Upgrade
|
Additional Paid-In Capital | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | Upgrade
|
Retained Earnings | 9.54 | 10.29 | 10.39 | 7.36 | 5.5 | Upgrade
|
Treasury Stock | -0.41 | -0.41 | -0.41 | -0.24 | -0.24 | Upgrade
|
Shareholders' Equity | 10.5 | 11.25 | 11.35 | 8.48 | 6.63 | Upgrade
|
Total Liabilities & Equity | 12.78 | 12.95 | 13.22 | 10.9 | 8.79 | Upgrade
|
Total Debt | - | - | - | - | 0.93 | Upgrade
|
Net Cash (Debt) | 5.4 | 6.83 | 5.47 | 2.9 | 2.52 | Upgrade
|
Net Cash Growth | -20.93% | 24.87% | 88.38% | 15.14% | -20.14% | Upgrade
|
Net Cash Per Share | 3.30 | 4.18 | 3.30 | 1.69 | 1.44 | Upgrade
|
Filing Date Shares Outstanding | 1.64 | 1.64 | 1.65 | 1.72 | 1.72 | Upgrade
|
Total Common Shares Outstanding | 1.64 | 1.64 | 1.65 | 1.72 | 1.72 | Upgrade
|
Working Capital | 9.06 | 9.7 | 10.12 | 7.58 | 6.65 | Upgrade
|
Book Value Per Share | 6.38 | 6.84 | 6.90 | 4.95 | 3.86 | Upgrade
|
Tangible Book Value | 10.5 | 11.25 | 11.35 | 8.48 | 6.63 | Upgrade
|
Tangible Book Value Per Share | 6.38 | 6.84 | 6.90 | 4.95 | 3.86 | Upgrade
|
Land | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | Upgrade
|
Buildings | 1.44 | 1.42 | 1.08 | 0.96 | 0.95 | Upgrade
|
Machinery | 2.04 | 2.05 | 1.98 | 1.65 | 1.59 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.